# Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

> **NCT02112526** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 21 (actual)

## Conditions studied

- Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT02112526
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-07
- **Primary completion:** 2020-06-30
- **Final completion:** 2024-10-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112526, "Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02112526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*